We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.

all report title image

PULMONARY ARTERIAL HYPERTENSION DRUG MARKET ANALYSIS

Pulmonary Arterial Hypertension Drug Market, by Drug Class (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, Others), by Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI203
Pages :163
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Expiration of key molecule patents
Drug-related side effects
Lack of awareness among people in emerging countries
High costs of diagnosis and treatment

Pulmonary Arterial Hypertension Drug Market Report Snapshots

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount

Press Release

Pulmonary Arterial Hypertension Drug Market to Surpass US$ 11,220.2 Mn by 2030

Credibility and Certifications

ESOMAR

DUNS Registered

Clutch

DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.